John Clayton Taylor - Sep 28, 2022 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC. (IDRA)

Role: Chief Executive Officer, Director
Signature: /s/ John J. Kirby, Attorney-in-Fact for John Clayton Taylor
Stock symbol: IDRA
Transactions as of: Sep 28, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/30/2022, 09:49 PM
Next filing: Jan 19, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IDRA	Common Stock, par value $0.001	Award		+2.17M			2.17M	Sep 28, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDRA	Series Z Convertible Preferred Stock	Award		+22.8K			22.8K	Sep 28, 2022	Common Stock	22.8M		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock").
F2	Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations.

Content

Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock").

Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations.